

Table 1.118A Any Use and Misuse of Prescription Sedative Subtypes in Past Year: Among People Aged 12 or Older; Misuse of Prescription Sedative Subtypes in Past Year: Among Past Year Any Users of Prescription Sedative Subtypes Aged 12 or Older; Numbers in Thousands, 2019 and 2020

Sedative Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2020)
ANY PRESCRIPTION SEDATIVE	15,636	<i>15,364</i>	1,098	<i>1,240</i>	1,098	<i>1,240</i>
Zolpidem Products	8,816	<i>8,050</i>	774	<i>807</i>	774	<i>807</i>
Eszopiclone Products	932	<i>991</i>	21	<i>54</i>	21	<i>54</i>
Zaleplon Products	414	<i>252</i>	25	*	*	*
Benzodiazepine Sedatives	1,729	<i>1,675</i>	68	<i>101</i>	68	<i>101</i>
Flurazepam	140	<i>113</i>	*	<i>16</i>	*	*
Temazepam Products	1,038	<i>898</i>	42	<i>83</i>	42	*
Triazolam Products	580	<i>689</i>	26	<i>27</i>	26	*
Barbiturates	510	<i>597</i>	44	<i>50</i>	*	*
Any Other Prescription Sedative ¹	5,441	<i>5,946</i>	237	<i>291</i>	237	<i>291</i>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of sedatives containing other active ingredients. Reports of misuse of “any other prescription sedative” that correspond only to the specific sedative categories shown in the table are excluded from estimates for Any Other Prescription Sedative and are included instead in the relevant sedative category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.118B Any Use and Misuse of Prescription Sedative Subtypes in Past Year: Among People Aged 12 or Older; Misuse of Prescription Sedative Subtypes in Past Year: Among Past Year Any Users of Prescription Sedative Subtypes Aged 12 or Older; Percentages, 2019 and 2020

Sedative Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2020)
ANY PRESCRIPTION SEDATIVE	5.7	5.5	0.4	<i>0.4</i>	7.0	<i>8.1</i>
Zolpidem Products	3.2	<i>2.9</i>	0.3	<i>0.3</i>	8.8	<i>10.0</i>
Eszopiclone Products	0.3	<i>0.4</i>	0.0	<i>0.0</i>	2.2	<i>5.4</i>
Zaleplon Products	0.2	<i>0.1</i>	0.0	*	*	*
Benzodiazepine Sedatives	0.6	<i>0.6</i>	0.0	<i>0.0</i>	3.9	<i>6.0</i>
Flurazepam	0.1	<i>0.0</i>	*	<i>0.0</i>	*	*
Temazepam Products	0.4	<i>0.3</i>	0.0	<i>0.0</i>	4.1	*
Triazolam Products	0.2	<i>0.2</i>	0.0	<i>0.0</i>	4.4	*
Barbiturates	0.2	<i>0.2</i>	0.0	<i>0.0</i>	*	*
Any Other Prescription Sedative ¹	2.0	<i>2.1</i>	0.1	<i>0.1</i>	4.3	<i>4.9</i>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of sedatives containing other active ingredients. Reports of misuse of “any other prescription sedative” that correspond only to the specific sedative categories shown in the table are excluded from estimates for Any Other Prescription Sedative and are included instead in the relevant sedative category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.119A Any Use and Misuse of Prescription Sedative Subtypes in Past Year: Among People Aged 12 to 17; Misuse of Prescription Sedative Subtypes in Past Year: Among Past Year Any Users of Prescription Sedative Subtypes Aged 12 to 17; Numbers in Thousands, 2019 and 2020

Sedative Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse		Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2020)
			in Past Year among Total Population (2019)	in Past Year among Total Population (2020)		
ANY PRESCRIPTION SEDATIVE	545	<i>429</i>	82	<i>35</i>	82	<i>35</i>
Zolpidem Products	143	<i>66</i>	38	<i>4</i>	*	*
Eszopiclone Products	17	<i>4</i>	4	<i>1</i>	*	*
Zaleplon Products	30	<i>6</i>	7	*	*	*
Benzodiazepine Sedatives	69	<i>25</i>	11	<i>5</i>	*	*
Flurazepam	10	<i>9</i>	3	<i>5</i>	*	*
Temazepam Products	23	*	2	*	*	*
Triazolam Products	39	<i>16</i>	6	*	*	*
Barbiturates	47	<i>15</i>	11	*	*	*
Any Other Prescription Sedative ¹	358	<i>324</i>	24	<i>20</i>	24	*

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of sedatives containing other active ingredients. Reports of misuse of “any other prescription sedative” that correspond only to the specific sedative categories shown in the table are excluded from estimates for Any Other Prescription Sedative and are included instead in the relevant sedative category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.119B Any Use and Misuse of Prescription Sedative Subtypes in Past Year: Among People Aged 12 to 17; Misuse of Prescription Sedative Subtypes in Past Year: Among Past Year Any Users of Prescription Sedative Subtypes Aged 12 to 17; Percentages, 2019 and 2020

Sedative Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2020)
ANY PRESCRIPTION SEDATIVE	2.2	<i>1.7</i>	0.3	<i>0.1</i>	15.1	<i>8.1</i>
Zolpidem Products	0.6	<i>0.3</i>	0.2	<i>0.0</i>	*	*
Eszopiclone Products	0.1	<i>0.0</i>	0.0	<i>0.0</i>	*	*
Zaleplon Products	0.1	<i>0.0</i>	0.0	*	*	*
Benzodiazepine Sedatives	0.3	<i>0.1</i>	0.0	<i>0.0</i>	*	*
Flurazepam	0.0	<i>0.0</i>	0.0	<i>0.0</i>	*	*
Temazepam Products	0.1	*	0.0	*	*	*
Triazolam Products	0.2	<i>0.1</i>	0.0	*	*	*
Barbiturates	0.2	<i>0.1</i>	0.0	*	*	*
Any Other Prescription Sedative ¹	1.4	<i>1.3</i>	0.1	<i>0.1</i>	6.8	*

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of sedatives containing other active ingredients. Reports of misuse of “any other prescription sedative” that correspond only to the specific sedative categories shown in the table are excluded from estimates for Any Other Prescription Sedative and are included instead in the relevant sedative category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.120A Any Use and Misuse of Prescription Sedative Subtypes in Past Year: Among People Aged 18 or Older; Misuse of Prescription Sedative Subtypes in Past Year: Among Past Year Any Users of Prescription Sedative Subtypes Aged 18 or Older; Numbers in Thousands, 2019 and 2020

Sedative Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse		Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2020)
			in Past Year among Total Population (2019)	in Past Year among Total Population (2020)		
ANY PRESCRIPTION SEDATIVE	15,091	<i>14,935</i>	1,016	<i>1,205</i>	1,016	<i>1,205</i>
Zolpidem Products	8,673	<i>7,984</i>	736	<i>803</i>	736	<i>803</i>
Eszopiclone Products	915	<i>987</i>	17	<i>52</i>	17	<i>52</i>
Zaleplon Products	384	<i>246</i>	19	<i>*</i>	<i>*</i>	<i>*</i>
Benzodiazepine Sedatives	1,660	<i>1,650</i>	57	<i>96</i>	57	<i>96</i>
Flurazepam	130	<i>104</i>	<i>*</i>	<i>*</i>	<i>*</i>	<i>*</i>
Temazepam Products	1,015	<i>898</i>	41	<i>83</i>	41	<i>*</i>
Triazolam Products	541	<i>673</i>	19	<i>27</i>	19	<i>*</i>
Barbiturates	463	<i>582</i>	33	<i>50</i>	<i>*</i>	<i>*</i>
Any Other Prescription Sedative ¹	5,083	<i>5,622</i>	212	<i>271</i>	212	<i>271</i>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of sedatives containing other active ingredients. Reports of misuse of “any other prescription sedative” that correspond only to the specific sedative categories shown in the table are excluded from estimates for Any Other Prescription Sedative and are included instead in the relevant sedative category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.120B Any Use and Misuse of Prescription Sedative Subtypes in Past Year: Among People Aged 18 or Older; Misuse of Prescription Sedative Subtypes in Past Year: Among Past Year Any Users of Prescription Sedative Subtypes Aged 18 or Older; Percentages, 2019 and 2020

Sedative Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2020)
ANY PRESCRIPTION SEDATIVE	6.0	5.9	0.4	0.5	6.7	8.1
Zolpidem Products	3.5	3.2	0.3	0.3	8.5	10.1
Eszopiclone Products	0.4	0.4	0.0	0.0	1.8	5.3
Zaleplon Products	0.2	0.1	0.0	*	*	*
Benzodiazepine Sedatives	0.7	0.7	0.0	0.0	3.4	5.8
Flurazepam	0.1	0.0	*	*	*	*
Temazepam Products	0.4	0.4	0.0	0.0	4.0	*
Triazolam Products	0.2	0.3	0.0	0.0	3.6	*
Barbiturates	0.2	0.2	0.0	0.0	*	*
Any Other Prescription Sedative ¹	2.0	2.2	0.1	0.1	4.2	4.8

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of sedatives containing other active ingredients. Reports of misuse of “any other prescription sedative” that correspond only to the specific sedative categories shown in the table are excluded from estimates for Any Other Prescription Sedative and are included instead in the relevant sedative category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.121A Any Use and Misuse of Prescription Sedative Subtypes in Past Year: Among People Aged 18 to 25; Misuse of Prescription Sedative Subtypes in Past Year: Among Past Year Any Users of Prescription Sedative Subtypes Aged 18 to 25; Numbers in Thousands, 2019 and 2020

Sedative Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population		Misuse in Past Year among Any Users of Sedative Subtypes (2019)	Misuse in Past Year among Any Users of Sedative Subtypes (2020)
			(2019)	(2020)	(2019)	(2020)
ANY PRESCRIPTION SEDATIVE	1,051	<i>1,066</i>	175	<i>251</i>	175	<i>251</i>
Zolpidem Products	436	<i>428</i>	120	<i>189</i>	120	*
Eszopiclone Products	35	<i>70</i>	4	<i>5</i>	*	*
Zaleplon Products	10	<i>13</i>	2	<i>*</i>	*	*
Benzodiazepine Sedatives	113	<i>146</i>	28	<i>16</i>	*	*
Flurazepam	12	<i>16</i>	3	<i>*</i>	*	*
Temazepam Products	38	<i>22</i>	20	<i>9</i>	*	*
Triazolam Products	75	<i>108</i>	12	<i>7</i>	*	*
Barbiturates	29	<i>57</i>	4	<i>5</i>	*	*
Any Other Prescription Sedative ¹	<i>572</i>	<i>500</i>	26	<i>40</i>	26	<i>40</i>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of sedatives containing other active ingredients. Reports of misuse of “any other prescription sedative” that correspond only to the specific sedative categories shown in the table are excluded from estimates for Any Other Prescription Sedative and are included instead in the relevant sedative category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.121B Any Use and Misuse of Prescription Sedative Subtypes in Past Year: Among People Aged 18 to 25; Misuse of Prescription Sedative Subtypes in Past Year: Among Past Year Any Users of Prescription Sedative Subtypes Aged 18 to 25; Percentages, 2019 and 2020

Sedative Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population		Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2020)
			(2019)	(2020)	(2019)	(2020)
ANY PRESCRIPTION SEDATIVE	3.1	3.2	0.5	0.7	16.6	23.5
Zolpidem Products	1.3	<i>1.3</i>	0.4	<i>0.6</i>	27.5	*
Eszopiclone Products	0.1	<i>0.2</i>	0.0	<i>0.0</i>	*	*
Zaleplon Products	0.0	<i>0.0</i>	0.0	*	*	*
Benzodiazepine Sedatives	0.3	<i>0.4</i>	0.1	<i>0.0</i>	*	*
Flurazepam	0.0	<i>0.0</i>	0.0	*	*	*
Temazepam Products	0.1	<i>0.1</i>	0.1	<i>0.0</i>	*	*
Triazolam Products	0.2	<i>0.3</i>	0.0	<i>0.0</i>	*	*
Barbiturates	0.1	<i>0.2</i>	0.0	<i>0.0</i>	*	*
Any Other Prescription Sedative ¹	1.7	<i>1.5</i>	0.1	<i>0.1</i>	4.6	8.1

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of sedatives containing other active ingredients. Reports of misuse of “any other prescription sedative” that correspond only to the specific sedative categories shown in the table are excluded from estimates for Any Other Prescription Sedative and are included instead in the relevant sedative category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.122A Any Use and Misuse of Prescription Sedative Subtypes in Past Year: Among People Aged 26 or Older; Misuse of Prescription Sedative Subtypes in Past Year: Among Past Year Any Users of Prescription Sedative Subtypes Aged 26 or Older; Numbers in Thousands, 2019 and 2020

Sedative Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse		Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2020)
			in Past Year among Total Population (2019)	in Past Year among Total Population (2020)		
ANY PRESCRIPTION SEDATIVE	14,040	<i>13,869</i>	841	<i>954</i>	841	<i>954</i>
Zolpidem Products	8,236	<i>7,556</i>	616	<i>613</i>	616	<i>613</i>
Eszopiclone Products	880	<i>917</i>	12	<i>47</i>	12	*
Zaleplon Products	374	<i>233</i>	16	*	*	*
Benzodiazepine Sedatives	1,547	<i>1,503</i>	29	<i>80</i>	29	<i>80</i>
Flurazepam	118	<i>88</i>	*	<i>12</i>	*	*
Temazepam Products	977	<i>875</i>	21	<i>74</i>	21	*
Triazolam Products	466	<i>565</i>	*	<i>20</i>	*	*
Barbiturates	434	<i>525</i>	29	<i>45</i>	*	*
Any Other Prescription Sedative ¹	4,510	<i>5,122</i>	186	<i>230</i>	186	<i>230</i>

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of sedatives containing other active ingredients. Reports of misuse of “any other prescription sedative” that correspond only to the specific sedative categories shown in the table are excluded from estimates for Any Other Prescription Sedative and are included instead in the relevant sedative category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.122B Any Use and Misuse of Prescription Sedative Subtypes in Past Year: Among People Aged 26 or Older; Misuse of Prescription Sedative Subtypes in Past Year: Among Past Year Any Users of Prescription Sedative Subtypes Aged 26 or Older; Percentages, 2019 and 2020

Sedative Subtype	Any Use	Any Use	Misuse	Misuse	Misuse	Misuse
	in Past Year (2019)	in Past Year (2020)	in Past Year among Total Population (2019)	in Past Year among Total Population (2020)	in Past Year among Past Year Any Users of Sedative Subtypes (2019)	in Past Year among Past Year Any Users of Sedative Subtypes (2020)
ANY PRESCRIPTION SEDATIVE	6.5	6.3	0.4	<i>0.4</i>	6.0	6.9
Zolpidem Products	3.8	3.5	0.3	<i>0.3</i>	7.5	8.1
Eszopiclone Products	0.4	<i>0.4</i>	0.0	<i>0.0</i>	1.4	*
Zaleplon Products	0.2	<i>0.1</i>	0.0	*	*	*
Benzodiazepine Sedatives	0.7	<i>0.7</i>	0.0	<i>0.0</i>	1.9	5.3
Flurazepam	0.1	<i>0.0</i>	*	<i>0.0</i>	*	*
Temazepam Products	0.5	<i>0.4</i>	0.0	<i>0.0</i>	2.2	*
Triazolam Products	0.2	<i>0.3</i>	*	<i>0.0</i>	*	*
Barbiturates	0.2	<i>0.2</i>	0.0	<i>0.0</i>	*	*
Any Other Prescription Sedative ¹	2.1	2.3	0.1	<i>0.1</i>	4.1	4.5

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

¹ Includes use or misuse of sedatives containing other active ingredients. Reports of misuse of “any other prescription sedative” that correspond only to the specific sedative categories shown in the table are excluded from estimates for Any Other Prescription Sedative and are included instead in the relevant sedative category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.